ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2149

Rheumatoid Arthritis: Patient’s Voice First! An Original Approach Based on Infodemiology Using Social Media Content – Results from the PRIMA Study
Abstract Number: 0777

Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients
Abstract Number: L11

Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
Abstract Number: 2151

Rheumatology on Reddit: A Descriptive Analysis
Abstract Number: 0210

Rheumatology, Heal Thyself: The Experience of Underrepresented Physicians in Rheumatology
Abstract Number: 1252

Rheuminating About Drugs, Sex, and Alcohol? Assessing the Informational Needs of Adolescents and Young Adults with Rheumatic Disease
Abstract Number: 1737

RheumMadness 2024: The Practical Impact of the Practically Perfect Season
Abstract Number: 1644

RISE Registry Associated with Significant Gains in Quality Measure Performance: An InterruptedTimes Series Analysis Before and After Participation
Abstract Number: 1086

Risk Factors Associated with Loss to Follow-up in a Prospective Gout Cohort
Abstract Number: 0527

Risk Factors for Leukopenia in Asian Patients with Rheumatoid Arthritis Undergoing Tocilizumab
Abstract Number: 2458

Risk Factors for Progression of Interstitial Lung Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2693

Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Abstract Number: 0453

Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family
Abstract Number: 2631

Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study
Abstract Number: 2261

Risk of Cervical Intraepithelial Neoplasia During Janus Kinase (JAK) Inhibitor Treatment in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].